Updated: Lilly posts 45% sales jump, culls four programs across obesity, Alzheimer's, heart failure and eczema

Kyle LaHucik

Senior Reporter

Eli Lilly said Thursday that its fourth-quarter revenue jumped 45% to $13.53 billion over the prior year, though this fell short of earlier projections. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Lilly posts 45% sales jump, culls four programs across obesity, Alzheimer's, heart failure and eczema

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bristol Myers launches fresh round of major cost cuts in bid to get ahead of patent cliff

AstraZeneca takes $753M charge on abandoned complement drug from Alexion deal

Pfizer hires Novartis oncology exec to steer its cancer ambitions

AstraZeneca offers some detail on China probe, reaffirms commitment to that market

J&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying the neuro drugmaker

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

Up­dat­ed: Lil­ly posts 45% sales jump, culls four pro­grams across obe­si­ty, Alzheimer's, heart fail­ure and eczema

Senior Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Updated: Lilly posts 45% sales jump, culls four programs across obesity, Alzheimer's, heart failure and eczema